Publications by authors named "Xiuting Lin"
Article Synopsis
- - The study aimed to find the maximum tolerated dose (MTD) and evaluate the safety and effectiveness of [Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer (mCRPC), involving 13 patients and a dose escalation protocol.
- - The results showed that the MTD was determined to be 1.85 GBq, with doses reaching up to 2.59 GBq causing dose-limiting myelosuppression, while patients experienced a decline in PSA levels after treatment cycles.
- - Overall, [Lu]Lu-LNC1003 was well tolerated at doses of 1.11 and 1.85 GBq per cycle, but careful monitoring of radiation doses to red